Merck & Co., Inc. (NYSE:MRK – Get Free Report) had its price objective upped by equities researchers at Guggenheim from $146.00 to $170.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price objective would indicate a potential upside of […]

Five Below (NASDAQ:FIVE – Get Free Report) had its price objective upped by equities researchers at JPMorgan Chase & Co. from $325.00 to $368.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the specialty retailer’s stock. JPMorgan Chase & Co.‘s target price would suggest […]

MongoDB (NASDAQ:MDB – Get Free Report) had its target price lifted by analysts at The Goldman Sachs Group from $453.00 to $520.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. The Goldman Sachs Group’s price target would suggest a potential upside of 36.97% from […]

MongoDB (NASDAQ:MDB – Get Free Report) had its price target lifted by Mizuho from $400.00 to $460.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Mizuho’s target price points to a potential upside of 5.94% from the company’s current price. Other equities research analysts […]

MongoDB (NASDAQ:MDB – Get Free Report) had its price objective increased by equities research analysts at Rosenblatt Securities from $395.00 to $445.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Rosenblatt Securities’ price objective indicates a potential upside of 2.48% from the company’s previous […]

PAVmed (NASDAQ:PAVM – Get Free Report) had its price target lifted by stock analysts at Ascendiant Capital Markets from $56.00 to $57.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Separately, Weiss Ratings downgraded shares of PAVmed from a “sell (d)” rating to a “sell […]

Affirm (NASDAQ:AFRM – Get Free Report) had its price objective hoisted by investment analysts at Morgan Stanley from $79.00 to $80.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley’s price target suggests a potential upside of 4.33% from the stock’s previous […]